Skip to main content
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. — Investor Relations & Filings

Ticker · DNLI ISIN · US24823R1059 LEI · 549300ZTQ2HO18L3Q830 US Manufacturing
Open in API
Filings indexed 748 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country US United States of America
Listing US DNLI

About Denali Therapeutics Inc.

https://www.denalitherapeutics.com

Denali Therapeutics Inc. is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases, lysosomal storage disorders, and other serious illnesses. The company's core scientific strategy centers on its proprietary Transport Vehicle™ (TV) platform, which is engineered to transport large therapeutic molecules, such as antibodies and enzymes, across the blood-brain barrier. This technology is designed to overcome a primary obstacle in treating diseases of the central nervous system. Denali's pipeline comprises a portfolio of investigational drug candidates that leverage this platform to target the underlying genetic and biological pathways of complex diseases.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-21 English
8-K - Denali Therapeutics Inc. (0001714899) (Filer)
Regulatory Filings
2026-05-07 English
ARS - Denali Therapeutics Inc. (0001714899) (Filer)
Annual Report
2026-04-21 English
8-K - Denali Therapeutics Inc. (0001714899) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 3, 2026, by Denali Therapeutics Inc. It announces the termination of a material definitive agreement (a collaboration agreement with Takeda Pharmaceutical Company). The content focuses on a specific event (termination of an agreement) rather than financial results, management changes, or other report types. The document is relatively short (3950 characters) and includes a press release as an exhibit. This type of filing is a regulatory announcement about a material event, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Annual Report, Earnings Release, or M&A filings. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2026-04-03 English
8-K - Denali Therapeutics Inc. (0001714899) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes details about a financial obligation created through a royalty funding agreement and the receipt of proceeds from this transaction. There is no detailed financial statement or comprehensive report content, but rather an announcement of a financing event. The document length is 3416 characters, which is relatively short and consistent with a current report announcement rather than a full financial report. The content focuses on a capital transaction and funding update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-03-31 English
SCHEDULE 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)
Major Shareholding Notification
2026-03-26 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.